\
&
Contact us
\
&
Contact us
About the programme
Specific Objective 5 – Deployment and Accelerating the Best Use of Technologies promotes the roll-out and best use of digital capacities, prioritising areas such as the support of SMEs and public authorities in their digital transformation.
Under the 2025-2027 main work programme, the following aspects will be covered:
marie.timmermann@fwo.be
+32 2 550 15 59
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Digital, Industry & Space EIT Deployment: Best use of technologies
The Co-Creation Accelerator is a programme run by 28DIGITAL (formerly EIT Digital). It brings together start-ups and industry partners to co-develop solutions to real-world challenges, with a focus on: Validating core technology (TRL 4-5 and above) Strengthening problem-solution fit Reducing technical and market uncertainty Building a cle... read more
Health EIT AI Continent Deployment: Best use of technologies
EIT Health’s Innovation Uptake Call focuses on mature digital, data-driven and AI-powered solutions and seeks to support the last steps towards commercialisation. Applicants must apply as a consortium of at least two independent legal entities from different countries. The consortium must include partners from at least two sides of the Knowl... read more
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
